Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms

Z G Zhang; Y M Rustum

Back

Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms

Journal article

Peer reviewed

Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms

Z G Zhang and Y M Rustum

Seminars in oncology, Vol.19(2 Suppl 4), pp.46-50

04/1992

PMID: 1532459

View Online

Abstract

Fluoropyrimidines, 5-fluorouracil (5-FU), and 5-fluorodeoxyuridine (FdUrd) are effective inhibitors of DNA synthesis. Inhibitory action is potentiated both in vitro and in vivo by the addition of leucovorin (LV; either the natural [6S] isomer or the mixture of the unnatural and natural [6R,S] isomers). The inhibition of DNA is subsequent to thymidylate synthase inhibition mediated by the formation of a covalently bound ternary complex consisting of 5-fluorodeoxyuridine monophosphate, 5,10-methylenetetrahydrofolate, and thymidylate synthase. In vitro exposure of cells to varying concentrations of [6R,S]LV or [6S]LV increases intracellular pools of the reduced folate cofactor. The effect of [6S]LV is both dose and time dependent. The in vitro effective concentration of [6S]LV is approximately 1 to 10 mumol/L, depending on cell type. While HCT-8 cells demonstrated optimal modulation of 5-FU and FdUrd cytotoxicity with 1 mumol/L of [6S]LV for 5 hours, the SE cells required higher doses of LV and longer exposure time. Thus, dependent on the cell type, higher concentration (10 mumol/L) and duration of exposure (greater than 5 hours) may be essential for an effective modulation of fluoropyrimidine action. Clinically, to achieve the concentration and conditions found optimal in an in vitro system, a dose of 500 mg/m2 by 5-hour infusion appears to be the present optimal dose and schedule of [6R,S]LV administration in combination with 5-FU.

Cecal Neoplasms - drug therapy

Cecal Neoplasms - metabolism

Drug Administration Schedule

Drug Synergism

Floxuridine - metabolism

Humans

Ileal Neoplasms - drug therapy

Ileal Neoplasms - metabolism

Kidney Neoplasms - drug therapy

Kidney Neoplasms - metabolism

Leucovorin - administration & dosage

Leucovorin - chemistry

Leucovorin - pharmacology

Stereoisomerism

Tetrahydrofolates - chemistry

Tetrahydrofolates - metabolism

Thymidylate Synthase - antagonists & inhibitors

Thymidylate Synthase - biosynthesis

Tumor Cells, Cultured

Details

Title: Subtitle: Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms
Creators: Z G Zhang - Roswell Park Cancer Institute
Y M Rustum
Resource Type: Journal article
Publication Details: Seminars in oncology, Vol.19(2 Suppl 4), pp.46-50
PMID: 1532459
ISSN: 0093-7754
eISSN: 1532-8708
Grant note: CA-21071 / NCI NIH HHS
Language: English
Date published: 04/1992
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984359767802771

Metrics

18 Record Views

16 Times Cited - Web of Science